Cernostics, a BFTP client focused on delivering next-generation cancer diagnostics and prognostics, raised $2.5 million in Series A1 financing, led by Illumina Ventures. With this capital investment, Cernostics will be able to intensify its clinical and market development for its TissueCypher® Barrett’s Esophagus Assay — the first test of its kind to predict the risk of development of deadly esophageal cancer in patients with Barrett’s esophagus. More
Client & Alumni News
Cernostics Raises $2.5 Million in Series A1 Financing
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.